CTOs on the Move

Corindus

www.corindus.com

 
Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company`s CorPath® System is the first FDA-cleared medical device to bring robotic-assisted precision to radial, coronary and peripheral procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance stents and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to radial and complex interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.corindus.com
  • 309 Waverley Oaks Road Suite 105
    Waltham, MA USA 02452
  • Phone: 508.653.3335

Executives

Name Title Contact Details

Funding

Corindus raised $45M on 02/28/2017

Similar Companies

LifeScan

LifeScan is a global leader in blood glucose monitoring innovation and digital health technology and has a vision to create a world without limits for people with diabetes and related conditions. More than 20 million people and their caregivers around the world count on LifeScan’s OneTouch brand products to manage their diabetes. Together, LifeScan and OneTouch improve the quality of life for people with diabetes with products and digital platforms defined by simplicity, accuracy, and trust.

InfiMed

InfiMed, Inc. is a Liverpool, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MicroLight Corporation of America

MicroLight Corporation of America is a Missouri City, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

North Coast Medical Inc

North Coast Medical Inc is a Gilroy, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

T2 Biosystems

At T2 Biosystems, we are united in our mission: to improve patient outcomes, lower mortality rates and reduce the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. By leveraging the power of our innovative and proprietary T2 Magnetic Resonance (T2MR) platform, T2 Biosystems’ diagnostics are designed to provide faster, easier and more accurate results than traditional methodologies. T2 Biosystems is currently targeting a range of critically underserved healthcare conditions, focusing initially on those for which a rapid diagnosis will serve an important dual role – saving lives and reducing costs. Our T2Candida Panel tackles sepsis and is the first FDA-cleared diagnostic panel requiring no blood culture – delivering more accurate results in hours versus days. Other ongoing development efforts include bacterial and hemostasis panels, as well as a Lyme disease partnership with Canon Life Sciences. Over 100 studies published in peer-reviewed journals have featured T2MR technology in a breadth of applications, including the direct detection and measurement of targets in various sample types, such as whole blood, plasma, serum, saliva, sputum and urine. With limits of detection as low as 1 CFU/mL, we believe T2MR technology will drive the next generation of diagnostics.